Clinical implementation of gene panel testing for lysosomal storage diseases. Issue 2 (11th December 2018)

• Record Type: Journal Article
• Authors: Gheldof, Alexander; Seneca, Sara; Stouffs, Katrien; Lissens, Willy; Jansen, Anna; Laeremans, Hilde; Verloo, Patrick; Schoonjans, An‐Sofie; Meuwissen, Marije; Barca, Diana; Martens, Geert; De Meirleir, Linda
• Is Part Of: Molecular genetics & genomic medicine. Volume 7:Issue 2(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-12-11
• Subjects: 4MU-based enzymatic testing -- diagnostic testing -- gene panel sequencing -- lysosomal storage disease -- next‐generation sequencing; Medical genetics -- Periodicals; Genomics -- Periodicals; 616.042
• DOI: 10.1002/mgg3.527
• Languages: English
• ISSNs: 2324-9269

Abstract

Abstract: Background: The diagnostic workup in patients with a clinical suspicion of lysosomal storage diseases (LSD) is often difficult due to the variability in the clinical phenotype. The gold standard for diagnosis of LSDs consists of enzymatic testing. However, due to the sequential nature of this methodology and inconsistent genotype–phenotype correlations of certain LSDs, finding a diagnosis can be challenging. Method: We developed and clinically implemented a gene panel covering 50 genes known to cause LSDs when mutated. Over a period of 18 months, we analyzed 150 patients who were referred for LSD testing and compared these results with the data of patients who were previously enrolled in a scheme of classical biochemical testing. Results: Our panel was able to determine the molecular cause of the disease in 22 cases (15%), representing an increase in diagnostic yield compared to biochemical tests developed for 21 LSDs (4.6%). We were furthermore able to redirect the diagnosis of a mucolipidosis patient who was initially suspected to be affected with galactosialidosis. Several patients were identified as being affected with neuronal ceroid lipofuscinosis, which cannot readily be detected by enzyme testing. Finally, several carriers of pathogenic mutations in LSD genes related to the disease phenotype were identified as well, thus potentially increasing the diagnostic yield of the panel as heterozygous deletions cannot be detected. Conclusion: We show that the implementation of a gene panel for LSD diagnostics results in an increased yield in comparison to classical biochemical testing. As the panel is able to cover a wider range of diseases, we propose to implement this methodology as a first‐tier test in cases of an aspecific LSD presentation, while enzymatic testing remains the first choice in patients with a more distinctive clinical presentation. Positive panel results should however still be enzymatically confirmed whenever possible. Abstract : The diagnosis of lysosomal storage diseases (LSD) can be challenging due to inconsistent genotype–phenotype correlations. We have clinically implemented an LSD gene panel and compared the diagnostic yield with that of classical biochemical testing. On the basis of this, we propose to use gene panel analysis as a first‐tier test in patients who are referred for LSD testing.